Circulating miR-210 and miR-1246 as potential biomarkers for differentiating hepatocellular carcinoma from metastatic tumors in the liver

Abstract

Summary Background To date few reports have pointed out the role of circulating miRNAs in discriminating metastatic liver tumors from primary hepatocellular (HCC) tumors. Such discrimination will have significant therapeutic and prognostic implications. The purpose of this study was to evaluate the potential value of a panel of HCC-related circulating miRNAs (miR-142, miR-182, miR-200a, mir-210, miR-211, miR-302b, miR-324, miR-338, miR-340 and miR-1246) as noninvasive biomarkers for discriminating primary HCC from metastatic tumors in the liver. Methods The expression level of the selected miRNAs was quantified by quantitative real time PCR in 33 patients with HCC, 22 patients with metastatic tumors in the liver, and 30 healthy volunteers as control. Mann-Whitney U test was used to evaluate the difference in miRNAs expression between primary and metastatic liver tumors and to study the associations between their relative expression levels and the clinicopathological factors. Receiver operating characteristic curve was used to evaluate the diagnostic value of the individual miRNAs. Results Statistical analyses revealed a differential expression in the level of serum miR-210 and miR-1246 between the two groups of patients. The sensitivity and specificity of miR-210, for differentiating HCC from metastatic malignancies in the liver were found to be 73.7% and 64.28%, respectively. Whilst, of miR-1246 were 72.2% and 67.8%, respectively. In addition, the differential expression of the two miRNAs was also found to be associated with clinicopathological parameters in the two studied groups. Conclusions Serum miR-210 and miR-1246 have some diagnostic value for discriminating patients with metastatic tumors to patients with primary HCC

Neurons can upregulate Cav-1 to increase intake of endothelial cells-derived extracellular vesicles that attenuate apoptosis via miR-1290

“…Further molecular characterization has shown that miR-1290 can attenuate apoptosis of primary neurons treated by OGD, although miR-1246 also exhibited similar effect but at a weaker strength as compared with miR-1290. Both miR-1290 and miR-1246 have been implicated in regulating cancer cell proliferation and migration, and exosomal miR-1290 and miR-1246 might serve as tumor biomarkers 53–57 . Our data have shown that these two miRNAs are highly enriched in ECs-derived EVs, supporting a neuronal protective role of ECs-derived EVs in stroke.…”

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

“…High miR-210 expression correlates with poor tumor-free and overall survival of HCC patients [243,245,246]. In addition, miR-210 can be used to discriminate HCC from other metastatic malignancies in the liver [247]. Moreover, miR-210 expression correlates in HCC with elevated tumor stages, vascular invasion and venous metastases indicating that miR-210 could promote metastasis of HCC [216], similarly as described in melanoma.…”

Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma

“…Recent study has demonstrated that miR-210 can be induced by hypoxia-inducible factor 1a (HIF-1a) to express in the tumor microenvironment, which correlates with unfavorable prognosis and greater resistance to chemoradiotherapy in pancreatic cancer (81). Ahmed et al (82). found that serum miR-210 had 73.7% sensitivity and 64.28% specificity in discriminating hepatocellular carcinoma from other metastatic liver cancers, respectively.…”